News stories about Taro Pharmaceutical Industries (NYSE:TARO) have trended positive on Tuesday, according to Accern Sentiment. The research firm ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Taro Pharmaceutical Industries earned a coverage optimism score of 0.26 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 45.1788426070925 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

These are some of the news headlines that may have effected Accern’s scoring:

Several brokerages recently commented on TARO. BidaskClub raised shares of Taro Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Thursday, September 28th. TheStreet cut shares of Taro Pharmaceutical Industries from a “b-” rating to a “c+” rating in a report on Wednesday, August 9th.

Taro Pharmaceutical Industries (NYSE TARO) opened at 114.14 on Tuesday. Taro Pharmaceutical Industries has a 52-week low of $92.28 and a 52-week high of $124.52. The firm has a market cap of $4.62 billion, a P/E ratio of 11.62 and a beta of 0.65. The stock has a 50 day moving average price of $105.36 and a 200 day moving average price of $111.39.

COPYRIGHT VIOLATION NOTICE: This article was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/10/03/taro-pharmaceutical-industries-taro-receiving-favorable-press-coverage-study-finds.html.

About Taro Pharmaceutical Industries

Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc (Taro Canada) and Taro U.SA The Company markets over 200 pharmaceutical products in over 25 countries.

Insider Buying and Selling by Quarter for Taro Pharmaceutical Industries (NYSE:TARO)

Receive News & Stock Ratings for Taro Pharmaceutical Industries Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries Ltd. and related stocks with our FREE daily email newsletter.